A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment

Expert Opinion on Drug Safety

Volumn 17, Issue 3, 2018, Pages 293-302

  Consoli, Agostino ^a   Formoso, Gloria ^a   Baldassarre, Maria Pompea Antonia ^a   Febo, Fabrizio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

cardiovascular; GLP 1 receptor agonists; outcome studies; safety; SGLT2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

AMPUTATION; BLOOD PRESSURE; BONE DISEASE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG SAFETY; HEART RATE; HUMAN; HYPOGLYCEMIA; PANCREAS DISEASE; PERIPHERAL VASCULAR DISEASE; REVIEW; UROGENITAL TRACT DISEASE; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85041501364     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2018.1428305     Document Type: Review

References (106)

1. Levin PA., Practical combination therapy based on pathophysiology of type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther. 2016;9:355–369.
2. Busch RS, Kane MP., Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med [Internet]. 2017;1–12. Available from https://www.tandfonline.com/doi/full/10.1080/00325481.2017.1342509%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/28657399
3. Wilding JPH, Rajeev SP, DeFronzo RA. Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. Diabetes Care [Internet]. 2016;39:S154–S164. Available from http://care.diabetesjournals.org/lookup/doi/10.2337/dcS15-3005
4. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
5. Sciences HH, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes the action to control cardiovascular risk in diabetes study group*. N Engl J Med. 2008;358:2545–2559.
6. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs [Internet]. 2015;75:33–59. [cited 2017 Oct26]. Available from http://link.springer.com/10.1007/s40265-014-0337-y
7. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol [Internet]. 2016;4:525–536. [cited 2017 Nov2]. Available from http://www.sciencedirect.com/science/article/pii/S2213858715004829?via%3Dihub
8. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab [Internet]. 2017;19:1353–1362. [cited 2017 Nov2]. Available from http://www.ncbi.nlm.nih.gov/pubmed/28432726
9. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab [Internet]. 2015 [cited 2017 Nov2];100:1927–1932. Available from http://www.ncbi.nlm.nih.gov/pubmed/25710563
10. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet] NEJMoa1612917. 2017. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1612917
11. Giorgino F, Benroubi M, Sun J-H, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241–2249.
12. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomesin Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311–322
13. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
14. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med [Internet]. 2015;373:2117–2128. [cited 2017 Nov2]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1504720
15. Cefalu WT, Leiter LA, De Bruin TWA, et al. Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38:1218–1227.
16. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
17. Administration F and D. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet]. 2015 [cited 2017 Nov6]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf.
18. European Medicines Agency. Risk of diabetic ketoacidosis to be examined; 12 June 2015 EMA/390062/2015 [Internet]. 2015 [cited 2017 Nov6]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/Procedure_started/WC500187926.pdf.
19. Chiasson J-L, Aris-Jilwan N, Bélanger R, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ [Internet]. 2003 [cited 2017 Nov7];168:859–866. Available from http://www.ncbi.nlm.nih.gov/pubmed/12668546
20. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig [Internet]. 2016;7:135–138. [cited 2017 Nov7]. Available from http://doi.wiley.com/10.1111/jdi.12401
21. European Medicines Agency. SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis [Internet]. 2016. [cited 2017 Nov7]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/02/WC500201890.pdf.
22. Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 inhibitor–associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther [Internet]. 2016;38:2654–2664.e1. [cited 2017 Nov6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28003053
23. Cooney MT, Vartiainen E, Laakitainen T, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J [Internet]. 2010. [cited 2017 Nov6];159:612–619.e3. Available from http://www.ncbi.nlm.nih.gov/pubmed/20362720
24. Li Y. Association between resting heart rate and cardiovascular mortality: evidence from a meta-analysis of prospective studies. Int J Clin Exp Med [Internet]. 2015;8:15329–15339. [cited 2017 Nov6]. Available from http://www.ncbi.nlm.nih.gov/pubmed/26629022
25. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open [Internet]. 2013;3:e001986. [cited 2017 Nov6]. Available from http://www.ncbi.nlm.nih.gov/pubmed/23355666
26. Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia [Internet]. 2012. [cited 2017 Dec1];55:1283–1290. Available from http://www.ncbi.nlm.nih.gov/pubmed/22286552
27. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med [Internet]. 2015. [cited 2017 Oct26];373:2247–2257. Available from http://www.ncbi.nlm.nih.gov/pubmed/26630143
28. Wroge J, Williams NT, Li L, et al. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgrad Med [Internet]. 2017;1–11. Available from http://m.jasn.asnjournals.org/content/early/2017/06/01/ASN.2016121372.abstract?papetoc%5Cnhttp://www.jasn.org/lookup/doi/10.1681/ASN.2016121372%5Cnwww.jasn.org
29. Goud A, Zhong J, Peters M, et al. GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep [Internet]. 2016 [cited 2017 6];18:16. Available from http://link.springer.com/10.1007/s11906-015-0621-6
30. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens [Internet]. 2014 [cited 2017 Nov6];27:130–139. Available from http://www.ncbi.nlm.nih.gov/pubmed/24263424
31. Oliva RV, Bakris GL. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens [Internet]. 2014;8:330–339. [cited 2017 Nov6]. Available from http://www.ncbi.nlm.nih.gov/pubmed/24631482
32. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes Vasc Dis Res [Internet]. 2015 [cited 2017 Nov6];12:90–100. Available from http://www.ncbi.nlm.nih.gov/pubmed/25589482
33. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens [Internet]. 2014 [cited 2017 Nov6];8:262–275.e9. Available from http://www.ncbi.nlm.nih.gov/pubmed/24602971
34. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care [Internet]. 2004 [cited 2017 Nov2];27:699–703. Available from http://www.ncbi.nlm.nih.gov/pubmed/14988288
35. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med [Internet]. 2013 [cited 2017 Nov15];369:1317–1326. Available from http://www.ncbi.nlm.nih.gov/pubmed/23992601
36. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
37. Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab [Internet]. 2017;43:2S13–2S19. Available from https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017233857&doi=10.1016%2FS1262-3636%2817%2930068-X&partnerID=40&md5=f35f150e492c41b7615b65aadf5be99b
38. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugsclinical perspective. Circulation [Internet]. 2017 [cited 2017 Nov2];136:249–259. Available from http://www.ncbi.nlm.nih.gov/pubmed/28522450
39. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med [Internet]. 2017 [cited 2017 Nov2];377:644–657. Available from http://www.nejm.org/doi/10.1056/NEJMoa1611925
40. Li L, Li S, Liu J, et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord [Internet]. 2016 [cited 2017 Nov2];16:91. Available from http://www.ncbi.nlm.nih.gov/pubmed/27169565
41. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med [Internet]. 2015 [cited 2017 Nov2];373:2247–2257. Available from http://www.nejm.org/doi/10.1056/NEJMoa1509225
42. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2016;375:311–322. [cited 2017 Nov2]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1603827
43. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2017 [cited 2017 Nov2];377:1228–1239. Available from http://www.ncbi.nlm.nih.gov/pubmed/28910237
44. Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction. JAMA [Internet]. 2016 [cited 2017 Nov16];316:500. Available from http://www.ncbi.nlm.nih.gov/pubmed/27483064
45. Gilbert RE. The perils of clinical trials. Kidney Int [Internet]. 2014;85:745–747. [cited 2017 Nov2]. Available from http://www.sciencedirect.com/science/article/pii/S0085253815562832
46. Seggelke SA, Lindsay MC, Hazlett I, et al. Cardiovascular safety of antidiabetic drugs in the hospital setting. Curr Diab Rep [Internet]. 2017;64:17. Available from http://link.springer.com/10.1007/s11892-017-0884-1
47. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
48. Hospital Discharge Rates for Nontraumatic Lower Extremity Amputation by Diabetes Status — united States, 1997 [Internet]. [cited 2017 Nov3]. Available from: https://www.cdc.gov/diabetes/statistics/lea/fig5.htm.
49. for Disease Control C. National Diabetes Statistics Report, 2017 Estimates of Diabetes and Its Burden in the United States Background. 2017. [cited 2017 Nov3]; Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
50. Fadini GP, Avogaro A, Schmidt C, et al. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol [Internet]. 2017;5:680–681. [cited 2017 Nov3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28733172
51. Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev [Internet]. 2004 [cited 2017 Nov28];20:411–417. Available from http://doi.wiley.com/10.1002/dmrr.499
52. Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes [Internet]. 2017 [cited 2017 Nov28];10:403–412. Available from http://www.ncbi.nlm.nih.gov/pubmed/29033597
53. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (London, England) [Internet]. 2009 [cited 2017 Nov28];374:39–47. Available from http://linkinghub.elsevier.com/retrieve/pii/S0140673609606590
54. Kanoski SE, Rupprecht LE, Fortin SM, et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology [Internet]. 2012 [cited 2017 Nov28];62:1916–1927. Available from http://linkinghub.elsevier.com/retrieve/pii/S002839081100579X
55. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab [Internet]. 2016;18:317–332. Available from http://www.ncbi.nlm.nih.gov/pubmed/26511102
56. Mosley JF, Smith L, Everton E, et al. Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. Pharm Ther [Internet]. 2015;40:451–462. Available from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4495872&tool=pmcentrez&rendertype=abstract
57. Howse PM, Chibrikova LN, Twells LK, et al. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and meta-analysis. Am J Kidney Dis [Internet]. 2016;68:733–742. Available from. DOI:10.1053/j.ajkd.2016.06.014
58. Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol [Internet]. 2017;16:65. Available from http://cardiab.biomedcentral.com/articles/10.1186/s12933-017-0547-1
59. Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol [Internet]. 2017;28:ASN.2016121372. Available from http://m.jasn.asnjournals.org/content/early/2017/06/01/ASN.2016121372.abstract?papetoc%5Cnhttp://www.jasn.org/lookup/doi/10.1681/ASN.2016121372%5Cnwww.jasn.org
60. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. Diabetes Care. 2016;39:222–230.
61. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
62. Yandrapalli S, Jolly G, Horblitt A, et al. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgrad Med. 2017 Nov;129(8):811–821.
63. Mosley JF, Smith L, Everton E, et al. Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. Pharm Ther. 2015;40:451–462.
64. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med [Internet]. 2016 [cited 2017 Dec3];375:323–334. Available from http://www.ncbi.nlm.nih.gov/pubmed/27299675
65. Tonneijck L, Smits MM, Muskiet MHA, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016;59:1412–1421.
66. Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15:197–207.
67. Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017.
68. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1351.
69. Invokana prescribing information [Internet]. 2017. [Cited 2017 Nov 7]. Available from: https://www.invokana.com/prescribing-information.pdf.
70. Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation [Internet]. 2016 [cited 2017 Nov3];134:752–772. Available from http://www.ncbi.nlm.nih.gov/pubmed/27470878
71. Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure. Circulation [Internet]. 2017;136:1643. Available from http://circ.ahajournals.org/content/136/17/1643.abstract
72. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin. Diabetes Care. 2013;36:4015–4021.
73. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
74. Häring HU, Merker L, Seewaldt-Becker E, et al. Empaglif lozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650–1659.
75. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815–1823.
76. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
77. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci Rep. 2017;7:1–11.
78. Larkin AT, Hoffman C, Stevens A, et al. Determinants of adherence to diabetes treatment. J Diabetes. 2015;7:864–871.
79. Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of acute pancreatitis. Eur J Gastroenterol Hepatol. 2013;25:225–231.
80. Malloy J, Gurney K, Shan K, et al. Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:419–424.
81. Andersen DK, Andren-Sandberg Å, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas. 2013;42:1227–1237.
82. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology [Internet]. 2011 [cited 2017 Oct23];141:150–156. Available from http://www.ncbi.nlm.nih.gov/pubmed/21334333
83. Forsmark CE. Incretins, diabetes, pancreatitis and pancreatic cancer: what the GI specialist needs to know. Pancreatology [Internet]. 2016;16:10–13. [cited 2017 Oct25]. Available from http://www.ncbi.nlm.nih.gov/pubmed/26795258
84. Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol [Internet]. 2013 [cited 2017 Oct25];50:569–577. Available from http://www.ncbi.nlm.nih.gov/pubmed/22008948
85. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595–2604.
86. Bonner-Weir S, In’t Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab [Internet]. 2014;16:661–666. [cited 2017 Oct25]. Available from http://www.ncbi.nlm.nih.gov/pubmed/24400596
87. Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med [Internet]. 2013 [cited 2017 Oct26];173:534–539. Available from http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2013.2720
88. Azoulay L, Filion KB, Platt RW, et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med [Internet]. 2016 [cited 2017 Oct23];176:1464. Available from http://www.ncbi.nlm.nih.gov/pubmed/27479930
89. Azoulay L, Filion KB, Platt RW, et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. Bmj. 2016;352:i581.
90. Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015;48:461–471.
91. Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes, Obes. Metab [Internet]. 2017;19:1233–1241. [cited 2017 Oct16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28244632
92. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int [Internet]. 2007;18:427–444. cited: http://www.ncbi.nlm.nih.gov/pubmed/17068657. 2017 Nov3.
93. Ivers RQ, Cumming RG, Mitchell P, et al. Diabetes and risk of fracture: the blue mountains eye study. Diabetes Care [Internet]. 2001 [cited 2017 Nov3];24:1198–1203. Available from http://www.ncbi.nlm.nih.gov/pubmed/11423502
94. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab [Internet]. 2007 [cited 2017 Nov3];92:1305–1310. Available from http://www.ncbi.nlm.nih.gov/pubmed/17264176
95. Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol [Internet]. 2016;81:78–88. [cited 2017 Nov3]. Available from http://www.ncbi.nlm.nih.gov/pubmed/27099876
96. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol [Internet]. 2015;3:8–10. [cited 2017 Nov3]. Available from http://www.ncbi.nlm.nih.gov/pubmed/25523498
97. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab [Internet]. 2016 [cited 2017 Nov3];101:157–166. Available from http://www.ncbi.nlm.nih.gov/pubmed/26580237
98. FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. [cited 2017 Nov3]; Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM461790.pdf.
99. Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther [Internet]. 2016 [cited 2017 Nov3];38:1299–1313. Available from http://www.ncbi.nlm.nih.gov/pubmed/27085585
100. Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab [Internet]. 2012 [cited 2017 Nov3];14:990–999. Available from http://www.ncbi.nlm.nih.gov/pubmed/22651373
101. Wu JHY, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol [Internet]. 2016;4:411–419. Available from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L609203272%5Cnhttp://dx.doi.org/10.1016/S2213-8587(16)00052-8%5Cnhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=22138595&id=doi:10.1016/S2213-8587(16)00052-8&atitle=Effects+of+sodi
102. Victoza prescribing information [Internet]. 2017. [Cited 2017 Nov 3]. Available from: http://www.novo-pi.com/victoza.pdf.
103. Reilly TP, Graziano MJ, Janovitz EB, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium–glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther [Internet]. 2014 [cited 2017 Dec3];5:73–96. Available from http://www.ncbi.nlm.nih.gov/pubmed/24474422
104. Lin H-W, Tseng C-H. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol [Internet]. 2014;2014:1–6. [cited 2017 Dec3]. Available from http://www.ncbi.nlm.nih.gov/pubmed/25254045
105. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid c-cells causing calcitonin release and C-cell proliferation. Endocrinology [Internet]. 2010 [cited 2017 Dec3];151:1473–1486. Available from http://www.ncbi.nlm.nih.gov/pubmed/20203154
106. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol [Internet]. 2016 [cited 2017 Dec3];4:1004–1016. Available from http://www.ncbi.nlm.nih.gov/pubmed/27651331